ArticleJournal of advanced research2026
The GOLM1-ACLY pathway regulates macrophage-secreted EFEMP1 via H3K27ac modifications to drive tumor progression.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMacrophages play crucial regulatory roles within the tumor immune microenvironment (TIME) and significantly influence tumor progression. GOLM1 has been identified as being closely associated with a variety of cancers. Nevertheless, the role of GOLM1 in macrophages on tumor progression remains unknown.
objectivesThis study aims to investigate the mechanism by which the GOLM1-ACLY axis in macrophages regulates tumor progression.
methodsThe orthotopic hepatocellular carcinoma (HCC) inoculationand subcutaneous tumor implantation were used to establish mouse tumor models. The expression levels of the indicated proteins were assessed by immunohistochemistry and immunoblotting. Coimmunoprecipitation (Co-IP), mass spectrometry (MS), and immunofluorescence were employed to determine the interactions between proteins. Bulk RNA sequencing was used to explore the mRNA profiles in bone marrow-derived monocytes (BMDMs). Moreover, qPCR was used to quantify the mRNA levels. CUT&Tag sequence and qPCR assays were performed to assess the DNA sequences bound by H3K27ac.
resultsWe identified that GOLM1 was observed to be markedly upregulated in macrophages from both liver/lung cancer patients and mouse tumor models. Macrophage deletion of GOLM1 suppressed tumor proliferation and provoked metabolic reprogramming in tumor cells. IP-MS analysis identified the Adenosine triphosphate citrate lyase (ACLY) protein as an interacting partner of GOLM1. Mechanistically, GOLM1 could bind to ACLY and impede the phosphorylation of ACLY by protein kinase A (PKA). The knockout of GOLM1 significantly increased the P-ACLY level in the nucleus of macrophage. Specifically, elevated P-ACLY significantly promoted monoacetylation at lysine 27 of histone H3 (H3K27ac). Combined analysis of CUT&Tag-seq and RNA-seq date further revealed a notable decrease of H3K27ac levels in the EFEMP1 gene, which promoted tumor proliferation via EGFR-MAPK/AKT signaling Genetic or pharmacological intervention via Acly-targeted siRNA or the ACLY inhibitor known as bempedoic acid (BA) abolished the tumor-suppressive effect induced by macrophage-specific GOLM1 deletion.
conclusionsOur findings reveal a novel mechanism involving the GOLM1-ACLY axis within macrophages that regulates tumor progression, which suggest a potential strategy for tumor intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.